CCR 20th Anniversary Commentary: BMS-247550-Microtubule Stabilization as Successful Targeted Therapy.

CCR 20th Anniversary Commentary: BMS-247550-Microtubule Stabilization as Successful Targeted Therapy. Clin Cancer Res. 2015 Mar 15;21(6):1237-1239 Authors: Pabla N, Sparreboom A Abstract In a landmark article published in the May 1, 2001, issue of Clinical Cancer Research, Lee and colleagues reported the original preclinical studies demonstrating anticancer activity of BMS-247550 (ixabepilone) against taxane-sensitive and taxane-resistant cancers. Subsequent clinical trials established the clinical efficacy of ixabepilone, leading to its regulatory approval for the treatment of drug-resistant metastatic or locally advanced breast cancers. Clin Cancer Res; 21(6); 1237-9. ©2015 AACR. See related article by Lee et al., Clin Cancer Res 2001;7(5) May 2001;1429-37. PMID: 25770292 [PubMed - as supplied by publisher]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research